{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:57:00Z","timestamp":1777960620764,"version":"3.51.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2018-04546"],"award-info":[{"award-number":["RGPIN-2018-04546"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["PGS-D"],"award-info":[{"award-number":["PGS-D"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1007495","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T13:33:46Z","timestamp":1574861626000},"page":"e1007495","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":56,"title":["Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-0017","authenticated-orcid":true,"given":"Tyler","family":"Cassidy","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-4770","authenticated-orcid":true,"given":"Morgan","family":"Craig","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"issue":"7","key":"pcbi.1007495.ref001","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"SJ Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"7378","key":"pcbi.1007495.ref002","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"I Mellman","year":"2011","journal-title":"Nature"},{"issue":"10","key":"pcbi.1007495.ref003","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"H Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"8","key":"pcbi.1007495.ref004","first-page":"473","article-title":"The Association of \u201cViral\u201d Hepatitis and Hodgkin\u2019s Disease","volume":"9","author":"HA Hoster","year":"1949","journal-title":"Cancer Res"},{"issue":"4","key":"pcbi.1007495.ref005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"EA Chiocca","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"pcbi.1007495.ref006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/v8020043","article-title":"To infection and beyond: The multi-pronged anti-cancer mechanisms of oncolytic viruses","volume":"8","author":"K Cassady","year":"2016","journal-title":"Viruses"},{"key":"pcbi.1007495.ref007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic viruses: Therapeutics with an identity crisis","volume":"9","author":"CJ Breitbach","year":"2016","journal-title":"EBioMedicine"},{"issue":"APR","key":"pcbi.1007495.ref008","first-page":"1","article-title":"Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer","volume":"9","author":"G Marelli","year":"2018","journal-title":"Front Immunol"},{"issue":"25","key":"pcbi.1007495.ref009","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"RHI Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"pcbi.1007495.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"PK Bommareddy","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"pcbi.1007495.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"H Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"6","key":"pcbi.1007495.ref012","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/cancers10060205","article-title":"Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer","volume":"10","author":"A Mostafa","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"17","key":"pcbi.1007495.ref013","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"J Chesney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"pcbi.1007495.ref014","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/cgt.2014.31","article-title":"Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land","volume":"21","author":"ZS Guo","year":"2014","journal-title":"Cancer Gene Ther"},{"issue":"25","key":"pcbi.1007495.ref015","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2015.62.5244","article-title":"Oncolytic virus-mediated immunotherapy: A combinatorial approach for cancer treatment","volume":"33","author":"SE Lawler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"pcbi.1007495.ref016","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"J Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"pcbi.1007495.ref017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"S Chaurasiya","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"pcbi.1007495.ref018","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones","volume":"26","author":"NT Martin","year":"2018","journal-title":"Mol Ther"},{"issue":"3","key":"pcbi.1007495.ref019","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/psp4.12063","article-title":"Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models","volume":"5","author":"RJ Allen","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"pcbi.1007495.ref020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2217\/fon.10.61","article-title":"From the evolution of toxin resistance to virtual clinical trials: the role of mathematical models in oncology","volume":"6","author":"Z Agur","year":"2010","journal-title":"Futur Oncol"},{"issue":"1","key":"pcbi.1007495.ref021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/1471-2105-14-221","article-title":"Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis","volume":"14","author":"BJ Schmidt","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"pcbi.1007495.ref022","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/bjc.2017.186","article-title":"Embracing model-based designs for dose-finding trials","volume":"117","author":"SB Love","year":"2017","journal-title":"Br J Cancer"},{"issue":"5","key":"pcbi.1007495.ref023","doi-asserted-by":"crossref","first-page":"190366","DOI":"10.1098\/rsos.190366","article-title":"In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model","volume":"6","author":"H Wang","year":"2019","journal-title":"R Soc Open Sci"},{"issue":"1","key":"pcbi.1007495.ref024","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"J Zhang","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"pcbi.1007495.ref025","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive Therapy","volume":"69","author":"RA Gatenby","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"pcbi.1007495.ref026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1083\/jcb.200404158","article-title":"Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis","volume":"166","author":"M Bentele","year":"2004","journal-title":"J Cell Biol"},{"issue":"12","key":"pcbi.1007495.ref027","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s11538-016-0179-8","article-title":"A mathematical model of granulopoiesis incorporating the negative feedback dynamics and kinetics of G-CSF\/neutrophil binding and internalization","volume":"78","author":"M Craig","year":"2016","journal-title":"Bull Math Biol"},{"key":"pcbi.1007495.ref028","article-title":"A mathematical model of viral oncology as an immuno-oncology instigator","author":"T Cassidy","year":"2019","journal-title":"Math Med Biol A J IMA"},{"issue":"5","key":"pcbi.1007495.ref029","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.3934\/mbe.2019270","article-title":"Equivalences between age structured models and state dependent distributed delay differential equations","volume":"16","author":"T Cassidy","year":"2019","journal-title":"Math Biosci Eng"},{"issue":"1","key":"pcbi.1007495.ref030","doi-asserted-by":"crossref","first-page":"23328","DOI":"10.1038\/srep23328","article-title":"Single-cell lineage tracking analysis reveals that an established cell line comprises putative cancer stem cells and their heterogeneous progeny","volume":"6","author":"S Sato","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"pcbi.1007495.ref031","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/cgt.2009.40","article-title":"Dynamics of multiple myeloma tumor therapy with a recombinant measles virus","volume":"16","author":"D Dingli","year":"2009","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"pcbi.1007495.ref032","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/mthe.2000.0130","article-title":"Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte\u2013Macrophage Colony-Stimulating Factor","volume":"2","author":"M Toda","year":"2000","journal-title":"Mol Ther"},{"issue":"6","key":"pcbi.1007495.ref033","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/1523-1747.ep12295238","article-title":"Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant","volume":"108","author":"BP Randazzo","year":"1997","journal-title":"J Invest Dermatol"},{"issue":"4","key":"pcbi.1007495.ref034","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000372-200308000-00003","article-title":"Tumor doubling time of cutaneous melanoma and its metastasis","volume":"25","author":"JA Carlson","year":"2003","journal-title":"Am J Dermatopathol"},{"key":"pcbi.1007495.ref035","first-page":"285","volume":"vol. 118","author":"PJ Klasse","year":"2015","journal-title":"Molecular Determinants of the Ratio of Inert to Infectious Virus Particles"},{"issue":"4","key":"pcbi.1007495.ref036","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/02841860600630954","article-title":"Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial","volume":"45","author":"R Stadler","year":"2006","journal-title":"Acta Oncol (Madr)"},{"key":"pcbi.1007495.ref037","first-page":"988","article-title":"Observations on growth rates of human tumors","volume":"76","author":"VP Collins","year":"1956","journal-title":"Amer J Roentgenol"},{"issue":"6","key":"pcbi.1007495.ref038","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/1097-0142(196111\/12)14:6<1272::AID-CNCR2820140618>3.0.CO;2-H","article-title":"A biomathematical approach to clinical tumor growth","volume":"14","author":"M Schwartz","year":"1961","journal-title":"Cancer"},{"key":"pcbi.1007495.ref039","unstructured":"MATLAB. R2017a. Natick, Massachusetts: The MathWorks Inc.; 2017."},{"issue":"July","key":"pcbi.1007495.ref040","article-title":"Genetic Algorithms","author":"JH Holland","year":"1992","journal-title":"Sci Am"},{"key":"pcbi.1007495.ref041","volume-title":"Adaptation in natural and artificial systems: An introductory analysis with applications to biology, control, and artificial intelligence","author":"JH Holland","year":"1975"},{"issue":"1","key":"pcbi.1007495.ref042","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cam.2004.07.034","article-title":"Genetic algorithms for modelling and optimisation","volume":"184","author":"J McCall","year":"2005","journal-title":"J Comput Appl Math"},{"issue":"4","key":"pcbi.1007495.ref043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biomedicines5010003","article-title":"Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies","volume":"5","author":"A Aitken","year":"2017","journal-title":"Biomedicines"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1007495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T13:34:25Z","timestamp":1574861665000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1007495"}},"subtitle":[],"editor":[{"given":"Aaron","family":"Goldman","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1007495","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/585711","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]}}}